## CPRT: Copart, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 -5.7% below STRENGTH zone (4.0-10.0%); PEG 2.22 fails VALUE criteria (<1.0); RSI 30 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($37.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Copart stock hits 52-week low at $38.66**
- Source: Investing.com | 20251201T093200 | Neutral | Relevance: 99%
- Copart Inc. stock has fallen to a new 52-week low of $38.66, reflecting a 37.15% decrease over the past year and a 39.4% decline from its 52-week high, with the RSI indicating oversold territory. Despite the price drop and a recent revenue miss in Q1 fiscal year 2026 earnings, InvestingPro data highlights Copart's "GREAT" financial health with more cash than debt and a strong Altman Z-Score. Investors are closely monitoring the company's performance amidst market challenges.

**2. New York State Common Retirement Fund Reduces Stock Position in Copart, Inc. $CPRT**
- Source: MarketBeat | 20251201T122325 | Neutral | Relevance: 99%
- The New York State Common Retirement Fund reduced its stake in Copart, Inc. by 23.5% in the second quarter, selling 335,226 shares. Despite this reduction, several other institutional investors increased their positions in CPRT, while company insiders sold a significant amount of shares. Wall Street analysts maintain a "Hold" rating on Copart with an average target price of $47.60, as the company recently exceeded EPS estimates but slightly missed on revenue.

**3. Copart stock hits 52-week low at $38.66 By Investing.com**
- Source: Investing.com Australia | 20251202T013400 | Neutral | Relevance: 99%
- Copart Inc. stock has hit a new 52-week low of $38.66, reflecting a 37.15% decrease over the past year and a 32.08% year-to-date decline. Despite the significant price drop and revenue miss in its recent Q1 fiscal year 2026 earnings, InvestingPro data indicates Copart maintains "GREAT" financial health with more cash than debt and a strong Altman Z-Score of 26.43. The stock is currently in oversold territory according to the RSI indicator.

**4. US$49.67: That's What Analysts Think Copart, Inc. (NASDAQ:CPRT) Is Worth After Its Latest Results**
- Source: 富途牛牛 | 20251130T092105 | Neutral | Relevance: 98%
- Analysts have re-evaluated Copart, Inc. (NASDAQ:CPRT) after its latest quarterly results, with shares down 6.3% following the announcement. Despite revenues being in line with predictions, the company delivered a slightly higher statutory profit of US$0.41 per share than expected. However, analysts are less bullish due to reduced revenue forecasts and a small dip in EPS expectations, leading to a 6.9% cut in their price target to US$49.67.

**5. Tsai Capital Corp Has $4.25 Million Stock Position in Copart, Inc. $CPRT**
- Source: MarketBeat | 20251130T134757 | Neutral | Relevance: 98%
- Tsai Capital Corp significantly increased its stake in Copart, Inc. (NASDAQ:CPRT) by 31.4% to hold 86,635 shares valued at $4.25 million, making it their 9th largest position. Other institutional investors like Norges Bank and Korea Investment Corp also made substantial moves in Copart stock. The article details recent analyst ratings, financial performance, and insider trading activities for Copart.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | JP Morgan | $45 | $50 | -10% |
| 2025-11-21 | Barclays | $33 | $32 | +3% |
| 2025-11-21 | Baird | $52 | $55 | -5% |
| 2025-11-12 | Barclays | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | JP Morgan | main | Neutral |
| 2025-11-21 | Barclays | main | Underweight |
| 2025-11-21 | Baird | main | Outperform |
| 2025-11-12 | Barclays | init | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($1.19M) |
| Sells | 2 ($10.88M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.3% (+2.4%)
- Blackrock Inc.: 6.5% (-2.4%)
- Principal Financial : 4.2% (+3.2%)
- State Street Corpora: 3.8% (+1.8%)
- JPMORGAN CHASE & CO: 2.7% (+86.7%)

### Key Risks

1. Heavy insider selling: $11M sold (2 transactions in 90 days).
2. Long-term trend broken: trading 22.2% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.22 elevated, pricing in significant growth expectations. Forward P/E 21.6x stretched relative to 10% growth. Quality metrics strong (ROA 11%, margin 34%). Balance sheet: strong liquidity (7.9x), low leverage (D/E 0.10). Analyst sentiment negative (2 target cuts vs 1 raises). Insider selling cluster ($10.9M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.12 |
| 52W Range | $38.18 - $63.85 |
| Short Interest | 3.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.22 |
| Forward P/E | 21.6 |
| Current P/E | 23.7 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -5.7% (minimal 5-day change). Below STRENGTH zone by 9.7pp (needs >4.0% for momentum thesis). AM_20 at -4.0% indicates price below own 20MA trend. Underperforming sector by 4.5pp, stock-specific weakness. Below SMA200 (0.78x), long-term trend not supportive. RSI oversold at 30, potential bounce setup.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.66% (CS: 10) | Weak |
| RSI_14 | 29.9 | Oversold |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 0.909x | Below |
| vs SMA200 | 0.778x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.96
- **Stop Loss:** $37.02 (5.0% risk)
- **Target:** $40.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 257
- **Position Value:** $10,012.72
- **Portfolio %:** 10.01%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-19 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $0.39 | $0.41 | +5.1% |
| 2025Q3 | $0.36 | $0.41 | +13.3% |
| 2025Q2 | $0.42 | $0.42 | +0.8% |
| 2025Q1 | $0.37 | $0.40 | +7.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*